Janssen Search
Search results
U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)
Mar 22, 2024 United States OPSYNVI ® combines two proven treatments with established efficacy and safety profiles into one tablet to be taken once daily, offering an option that helps to support the implementation of clinical guideline recommendations for ...
About Our Immunology Innovations
Redefining Treatment by Pioneering Pathway Science Retrovirus At Janssen Immunology, our vision is to restore health for the millions of people living with immune disease. Our approach to achieving this aspirational vision is systematic and evidence ...
Mental Health Partnerships in Asia Pacific
Fostering Mental Health Partnerships in Asia Pacific In Asia Pacific, as in many regions around the world, there is a stigma surrounding mental illness, resulting from a lack of awareness and education about mental health disorders. Despite their high ...
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non–muscle-invasive bladder cancer, respectively
May 05, 2024 Updated results reinforce the potential of TAR-210 to transform treatment of non – muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations SAN ANTONIO, May 5, 2024 – Johnson & Johnson announced today ...
Why it’s Important to Celebrate International Women’s Day
Why it’s Important to Celebrate International Women’s Day Recently, we celebrated International Women's Day (IWD), a global awareness day paying special tribute to the social, economic, cultural and political achievements of women. IWD is ...
Fighting Multi-Drug Resistant Tuberculosis
Fighting Multi-Drug Resistant Tuberculosis (MDR-TB) Creating Long-Term, Sustainable Solutions More than 480,000 new cases of multi-drug resistant tuberculosis (MDR-TB) were reported worldwide in 2013, and only 20 percent of MDR-TB patients were enrolled ...
Janssen Provides Portfolio Update
Mar 29, 2023 United States RARITAN, N.J., March 29, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson disclosed today that following a review of its portfolio to prioritize the most transformational assets for ongoing investment, and an ...
Transparency and Collaboration
Transparency and Collaboration At Janssen, we believe transparency helps to advance science and medicine; it’s in the best interests of both the people who use our pharmaceutical products and providers who prescribe them. The people and healthcare ...
Twenty Years of Progress in Search for an HIV Vaccine
Twenty Years of Progress in Search for an HIV Vaccine The world’s inaugural HIV Vaccine Awareness Day (HVAD) was held 20 years ago. HVAD was created in 1998 to commemorate U.S. President Bill Clinton’s declaration that the world needed – and was capable ...
Celebrating Our Progress toward an Effective HIV Vaccine
Celebrating Our Progress toward an Effective HIV Vaccine Today marks an exciting milestone: the full enrollment of volunteers in the first efficacy study for Janssen’s investigational preventive HIV vaccine. The Imbokodo study is designed to help ...